Business Context and Reporting Period
This Form 8-K is filed by OncoGenex Pharmaceuticals, Inc. (noted as "ACHIEVE LIFE SCIENCES, INC." in metadata) on March 9, 2016. The report announces the financial results for the fourth quarter and the full year ended December 31, 2015.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus prior periods in the main text. It serves as a notification that the results for the period ended December 31, 2015, have been issued.
Guidance, Outlook, and Risks
The text does not contain specific guidance, outlook, management commentary, or risk factors. It states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 9, 2016) for actual financial figures.
- Verify the discrepancy between the metadata company name ("ACHIEVE LIFE SCIENCES, INC.") and the registrant name in the filing ("ONCOGENEX PHARMACEUTICALS, INC.").
- Confirm the specific revenue and net loss figures for Q4 and FY 2015 from the attached press release.
- Check for any updated cash runway or funding requirements mentioned in the press release.